"10.1371_journal.pone.0098152","plos one","2014-05-27T00:00:00Z","Caitlyn T Solem; Sonya J Snedecor; Alexandra Khachatryan; Katherine Nedrow; Margaret Tawadrous; Richard Chambers; Seema Haider; Kit Simpson","Pharmerit International, Bethesda, Maryland, United States of America; Pfizer Inc, Groton, Connecticut, United States of America; Pfizer Inc, Collegeville, Philadelphia, United States of America; Medical University of South Carolina, Charleston, South Carolina, United States of America","Conceived and designed the experiments: CS SS AK. Performed the experiments: CS SS AK. Analyzed the data: CS SS AK KN MT RC SH KS. Contributed reagents/materials/analysis tools: CS SS AK. Wrote the paper: CS SS AK KN MT RC SH KS.","The authors have read the journals policy and have the following conflicts: CS, SS, and AK were employees of Pharmerit International at the time the study was completed, which received consulting fees from Pfizer Inc on behalf of ViiV Healthcare, the developer of dolutegravir. KN, MT, RC, and SH were employees and/or shareholders of Pfizer Inc at the time the study was completed. KS received consulting fees from Pfizer Inc. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","05","Caitlyn T Solem","CTS",8,TRUE,3,3,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
